Metabolic effects of switching Kaletra [lopinavir/ritonavir] to boosted Reyataz [atazanavir]

Trial Profile

Metabolic effects of switching Kaletra [lopinavir/ritonavir] to boosted Reyataz [atazanavir]

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2010

At a glance

  • Drugs Atazanavir; Lopinavir/ritonavir; Ritonavir
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Feb 2009 Status changed from recruiting to completed, as reported by
    • 22 Jan 2008 The expected completion date for this trial is now 1 Dec 2008 as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top